Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers

Journal of Clinical Pharmacology

Volumn 44, Issue 9, 2004, Pages 991-1002

  Ramakrishnan, Rohini ^a   Cheung, Wing K ^b   Wacholtz, Mary C ^b   Minton, Neil ^b   Jusko, William J ^a  

^a UNIVERSITY AT BUFFALO   (United States)

^b JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Dosing; Erythropoietin; Pharmacodynamics; Pharmacokinetics; Recombinant human erythropoietin

Indexed keywords

HEMOGLOBIN; IRON; RECOMBINANT ERYTHROPOIETIN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISPOSITION; DRUG MECHANISM; ERYTHROCYTE COUNT; ERYTHROPOIESIS; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; HUMAN EXPERIMENT; MALE; MULTIPLE DRUG DOSE; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; RETICULOCYTE COUNT; SINGLE BLIND PROCEDURE; SINGLE DRUG DOSE;

ALGORITHMS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CELL COUNT; ERYTHROCYTES; ERYTHROPOIESIS; ERYTHROPOIETIN, RECOMBINANT; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; INJECTIONS, SUBCUTANEOUS; MODELS, STATISTICAL; RETICULOCYTES;

EID: 4143136302     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004268411     Document Type: Article

References (31)

1. Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol Rev. 1992;72:449-489.
2. Lappin TR, Rich IN. Erythropoietin - the first 90 years. Clin Lab Haematol. 1996;18:137-145.
3. Markham A, Bryson HM. Epoetin alfa: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applications. Drugs. 1995;49:232-254.
4. Thatcher N. Management of chemotherapy-induced anemia in solid tumors. Semin Oncol. 1998;25:23-26.
5. Goldberg MA, McCutchen JW, Jove M, et al. A safety and efficacy comparison study of two dosing regimens of epoetin alfa in patients undergoing major orthopedic surgery. Am J Orthop. 1996;25:544-552.
6. Cheung WK, Goon BL, Guilfoyle MC, Wacholtz MC. Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects. Clin Pharmacol Ther. 1998;64:412-423.
7. McMahon FG, Vargas R, Ryan M, et al. Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy volunteers. Blood. 1990;76:1718-1722.
8. Veng-Pedersen P, Widness JA, Pereira LM, Schmidt RL, Lowe LS. Kinetic evaluation of non-linear drug elimination by a disposition decomposition analysis: application to the non-linear elimination kinetics of erythropoietin in adult human. J Pharm Sci. 1995;84:760-767.
9. Egrie JC, Cotes PM, Jone J, Gaines Das RE, Tam RC. Development of radioimmunoassays for human erythropoietin using recombinant erythropoietin as tracer and immunogen. J Immunol Methods. 1987;99:235-240.
10. D'Argenio DZ, Schumitzky A. ADAPT II User's Guide: Pharmacokinetic/ Pharmacodynamic Systems Analysis Software. Los Angeles: Biomedical Simulations Resource; 1997.
11. Gillespie WR. PCDCON: Deconvolution for Pharmacokinetic Analysis. Austin: University of Texas; 1991.
12. Yeh KC, Kwan CK. A comparison of numerical integrating algorithms by trapezoidal, LaGrange, and spline approximation. J Pharmacokin Biopharm. 1978;6:79-98.
13. Ramakrishnan R, Cheung WK, Farrell F, Joffee L, Jusko WJ. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous dose administration in cynomolgus monkeys. J Pharmacol Exp Ther. 2003;306:1-8.
14. Mohandas N, Groner W. Cell membrane and volume changes during red cell development and aging. Ann N Y Acad Sci. 1989;554: 217-224.
15. Guyton AC. Textbook of Medical Physiology. Philadelphia: W. B. Saunders; 1996.
16. Flaharty KK, Caro J, Erslev A, et al. Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men. Clin Pharmacol Ther. 1990;47:557-564.
17. Salmonson T, Danielson BG, Wikstrom B. The pharmacokinetics of recombinant human erythropoietin after intravenous and subcutaneous administration to healthy subjects. Br J Clin Pharmaco. 1990; 29:709-713.
18. Kato M, Kamiyama H, Okazaki A, Kumaki K, Kato Y, Sugiyama Y. Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats. J Pharmacol Exp Ther. 1997;283:520-527.
19. Radwanski E, Chakraborty A, Van Wart S, et al. Pharmacokinetics and leukocyte responses of recombinant human interleukin-10. Pharm Res. 1998;15:1895-901.
20. Lajtha LG. Recent studies in erythroid differentiation and proliferation. Medicine. 1964;43:625-633.
21. Maxwell AP, Lappin TRJ. Pharmacokinetics and pharmacodynamics of r-HuEpo. Erythropoiesis: New Dimensions in the Treatment of Anaemia. 1995;6:46-53.
22. Henry JB. Clinical Diagnosis and Management by Laboratory Methods. Philadelphia: W. B. Saunders; 2001.
23. Kaufman JS, Reda DJ, Fye CL, et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med. 1998;339:578-583.
24. Besarab A, Flaharty KK, Erslev AJ, et al. Clinical pharmacology and economics of recombinant human erythropoietin in end-stage renal disease: the case for subcutaneous administration. J Am Soc Nephrol. 1992;2:1405-1416.
25. Necas E, Neuwirt J. Feedback regulation by red cell mass of the sensitivity of the erythropoietin-producing organ to hypoxia. Blood. 1970;36:754-763.
26. Lindemann R. Erythropoiesis inhibiting factor(s) in intact and haemolyzed red blood cells. Scand J Haematol. 1975;14:216-225.
27. Birkhill FR, Maloney MA, Levenson SM. Effect of transfusion polycythemia upon bone marrow activity and erythrocyte survival in man. Blood. 1951;6:1021-1033.
28. Weber JP, Walsh PC, Peters CA, Spivak JL. Effect of reversible androgen deprivation on hemoglobin and serum immunoreactive erythropoietin in men. Am J Hematol. 1991;36:190-194.
29. Udupa KB, Crabtree HM, Lipschitz DA. In vitro culture of proerythroblasts: characterization of proliferative response to erythropoietin and steroids. Br J Haematol. 1986;62:705-714.
30. Peschle C, Rappaport IA, Sasso GF, Condorelli M, Gordon AS. The role of estrogen in the regulation of erythropoietin production. Endocrinology. 1973;92:358-362.
31. Ifudu O. Patient characteristics determining rHuEpo dose requirements. Nephrol Dial Transplant. 2002;17:38-41.